Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple blood test tell who needs more cancer treatment?

NCT ID NCT06287814

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 19, 2026 · Updated 3 times

Summary

This study is testing whether a blood test that looks for cancer DNA (called a liquid biopsy) can find leftover cancer cells after surgery in people with stage III colorectal cancer. The goal is to see if this test can help doctors decide who needs additional treatment and who can safely avoid it. The study will follow 70 patients for three years to see how well the test predicts cancer return.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liquid biopsy (ctDNA blood test)
What this could lead to
If successful, this could help doctors know which patients need more treatment after surgery and which do not, reducing unnecessary side effects.
What could go wrong
This is an early-stage observational study with only 70 participants. The tests may not be accurate enough to guide treatment decisions yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Oct 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

PART All patients with resected stage I to III CRC PART II Patients with stage III CRC with adjuvant chemotherapy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

FRENCH.MRD.CRC PART I Inclusion criteria * Colon or rectal cancer, clinical tumor stage I-III. * Patient 18 years or older. * Scheduled for curative intent resection surgery (including "compromised" curative resections). Exclusion criteria * Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome. * Verified distant metastases. * Malignant colorectal polyps diagnosed after polypectomy. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study. * Pregnant or nursing woman, or in childbearing age and not willing to use contraception * Protected and vulnerable adult * Not covered by Health insurance * Patient unable to understand and sign written informed consent. FRENCH.MRD.CRC PART II Inclusion criteria * Participation in FRENCH.MRD.CRC part 1 - SURGERY * Colorectal cancer, UICC stage III * Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer * Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included) * Treated with neoadjuvant chemo-radiation therapy * Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma) * Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Montpellier

    RECRUITING

    Montpellier, Hérault, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.